Understanding Down Syndrome
- Published27 Mar 2023
- Author Karen Weintraub
- Source BrainFacts/SfN
Down syndrome is named for the English physician who first described it in 1866, but nearly 100 years passed before scientists determined what caused the condition: possessing an extra copy of all or part of the 21st chromosome.
People with this syndrome have three copies of this genetic material, instead of two. In some cases, the extra copy, or trisomy, does not occur in every cell, producing what’s known as mosaicism. *Around 6,000 babies are born each year with Down syndrome in the United States, with the condition occurring in about one in every 700 births.
There is no clear cause of the genetic condition, although maternal age is a major risk factor for Down syndrome. Women who become pregnant at 35 and older are more likely to have a pregnancy affected by Down syndrome when compared to women who become pregnant at a younger age.
Since late 2011, fetuses can be screened for Down syndrome using the mother’s blood. In the past, the risk of test procedures meant that only older mothers (whose likelihood of having a Down syndrome child was known to be higher) should be screened. Younger mothers didn’t know until delivery whether their child would have Down syndrome. The blood test, unlike other more invasive prenatal checks for birth defects and genetic abnormalities like amniocentesis and chorionic villus sampling, poses no risk to the baby, so it can also be used for younger mothers whose chance of having a child with Down syndrome is quite small.
Children born with Down syndrome have distinctive facial features, including a flattened face and bridge of the nose, eyes that slant upward, and small ears. They usually have small hands and feet, short stature, and poor muscle tone as well. The intellectual abilities of people with Down syndrome are typically low to moderate, although some people graduate from high school and college, and many successfully hold jobs. Other symptoms of Down syndrome can include hearing loss and heart defects, and virtually everyone born with Down syndrome will develop early-onset Alzheimer’s disease, often in their 40s or 50s. Chromosome 21 contains the gene that encodes amyloid precursor protein (APP), an Alzheimer’s disease risk factor, and possessing an extra copy of this gene might cause the early onset of the disease. Interestingly, people with mosaic Down syndrome seem to have milder symptoms and are more likely to live past 50.
There is no real treatment for Down syndrome, nor any clear explanation of what occurs in the brain. Poor connections among nerve cells in the hippocampus, the part of the brain involved in memory (and the first brain area affected by Alzheimer’s disease), are believed to be a key factor in brain or intellectual differences in Down syndrome. Dysfunction in the mitochondria, the cell’s power plants, might also play a role in development of related disorders that involve energy metabolism, such as diabetes.
Scientists have grown stem cells from fetuses with Down syndrome and used them to test potential treatments and confirm which molecular pathways are involved in the condition. In one such laboratory study, researchers took a gene that typically inactivates the second X chromosome in female mammals and spliced it into a stem cell that had three copies of chromosome 21. In these cells, the inactivation gene muted the expression of genes on the extra chromosome 21, believed to contribute to Down syndrome. Although this is a long way from any clinical applications, the model is being used to test the changes and cellular problems that occur with the tripling of the 21st chromosome, in hopes of eventually finding a treatment.
Adapted from the 8th edition of Brain Facts by Karen Weintraub.
*This statistic was updated March 27, 2023, to reflect the most recent CDC data on Down syndrome prevalence.
CONTENT PROVIDED BY
Allen, E. G., Freeman, S. B., Druschel, C., Hobbs, C. A., O'Leary, L. A., Romitti, P. A., Royle, M. H., Torfs, C. P., & Sherman, S. L. (2009). Maternal age and risk for trisomy 21 assessed by the origin of chromosome nondisjunction: a report from the Atlanta and National Down Syndrome Projects. Human genetics, 125(1), 41–52. https://doi.org/10.1007/s00439-008-0603-8
Barbaresi, W. J., Colligan, R. C., Weaver, A. L., Voigt, R. G., Killian, J. M., & Katusic, S. K. (2013). Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD: a prospective study. Pediatrics, 131(4), 637–644. https://doi.org/10.1542/peds.2012-2354
Bishop D. V. (2015). The interface between genetics and psychology: lessons from developmental dyslexia. Proceedings. Biological sciences, 282(1806), 20143139. https://doi.org/10.1098/rspb.2014.3139
Casanova, J. R., Nishimura, M., & Swann, J. W. (2014). The effects of early-life seizures on hippocampal dendrite development and later-life learning and memory. Brain research bulletin, 103, 39–48. https://doi.org/10.1016/j.brainresbull.2013.10.004
Casanova, M. (2015). The Neuropathology of Autism. In: Fatemi, S. (eds) The Molecular Basis of Autism. Contemporary Clinical Neuroscience. Springer, New York, NY. 153-171. https://doi.org/10.1007/978-1-4939-2190-4_8
Christensen, D. L., Baio, J., Braun, K. V., Bilder, D., Charles, J., Constantino, J. N., Daniels, J., Maureen, S. Durkin, M. S., Robert, T., Fitzgerald, R. T., Kurzius-Spencer, M., Lee, L., Pettygrove, S., Robinson, C., Schulz, E., Wells, C., Wingate, M. S., Zahorodny, W., Yeargin-Allsopp, M. (2016). Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. MMWR Surveill Summ 2016;65(No. SS-3)(No. SS-3):1–23. DOI: http://dx.doi.org/10.15585/mmwr.ss6503a1external icon.
Chronis-Tuscano, A., Molina, B. S., Pelham, W. E., Applegate, B., Dahlke, A., Overmyer, M., & Lahey, B. B. (2010). Very early predictors of adolescent depression and suicide attempts in children with attention-deficit/hyperactivity disorder. Archives of general psychiatry, 67(10), 1044–1051. https://doi.org/10.1001/archgenpsychiatry.2010.127
Durkin, M. S., Maenner, M. J., Newschaffer, C. J., Lee, L. C., Cunniff, C. M., Daniels, J. L., Kirby, R. S., Leavitt, L., Miller, L., Zahorodny, W., & Schieve, L. A. (2008). Advanced parental age and the risk of autism spectrum disorder. American journal of epidemiology, 168(11), 1268–1276. https://doi.org/10.1093/aje/kwn250
Emerson, R. W., Adams, C., Nishino, T., Hazlett, H. C., Wolff, J. J., Zwaigenbaum, L., Constantino, J. N., Shen, M. D., Swanson, M. R., Elison, J. T., Kandala, S., Estes, A. M., Botteron, K. N., Collins, L., Dager, S. R., Evans, A. C., Gerig, G., Gu, H., McKinstry, R. C., Paterson, S., … Piven, J. (2017). Functional neuroimaging of high-risk 6-month-old infants predicts a diagnosis of autism at 24 months of age. Science translational medicine, 9(393), eaag2882. https://doi.org/10.1126/scitranslmed.aag2882
Finn, E. S., Shen, X., Holahan, J. M., Scheinost, D., Lacadie, C., Papademetris, X., Shaywitz, S. E., Shaywitz, B. A., & Constable, R. T. (2014). Disruption of functional networks in dyslexia: a whole-brain, data-driven analysis of connectivity. Biological psychiatry, 76(5), 397–404. https://doi.org/10.1016/j.biopsych.2013.08.031
Fisch, H., Hyun, G., Golden, R., Hensle, T. W., Olsson, C. A., & Liberson, G. L. (2003). The influence of paternal age on down syndrome. The Journal of urology, 169(6), 2275–2278. https://doi.org/10.1097/01.ju.0000067958.36077.d8
Frazier, T. W., Klingemier, E. W., Beukemann, M., Speer, L., Markowitz, L., Parikh, S., Wexberg, S., Giuliano, K., Schulte, E., Delahunty, C., Ahuja, V., Eng, C., Manos, M. J., Hardan, A. Y., Youngstrom, E. A., & Strauss, M. S. (2016). Development of an Objective Autism Risk Index Using Remote Eye Tracking. Journal of the American Academy of Child and Adolescent Psychiatry, 55(4), 301–309. https://doi.org/10.1016/j.jaac.2016.01.011
Geschwind, D. H., & State, M. W. (2015). Gene hunting in autism spectrum disorder: on the path to precision medicine. The Lancet. Neurology, 14(11), 1109–1120. https://doi.org/10.1016/S1474-4422(15)00044-7
Guastella, A. J., & Hickie, I. B. (2016). Oxytocin Treatment, Circuitry, and Autism: A Critical Review of the Literature Placing Oxytocin Into the Autism Context. Biological psychiatry, 79(3), 234–242. https://doi.org/10.1016/j.biopsych.2015.06.028
Hallmayer, J., Cleveland, S., Torres, A., et al. Genetic Heritability and Shared Environmental Factors Among Twin Pairs With Autism. Arch Gen Psychiatry. 2011;68(11):1095–1102. doi:10.1001/archgenpsychiatry.2011.76
Helguera, P., Seiglie, J., Rodriguez, J., Hanna, M., Helguera, G., & Busciglio, J. (2013). Adaptive downregulation of mitochondrial function in down syndrome. Cell metabolism, 17(1), 132–140. https://doi.org/10.1016/j.cmet.2012.12.005
Hornig, M., Bresnahan, M. A., Che, X., Schultz, A. F., Ukaigwe, J. E., Eddy, M. L., Hirtz, D., Gunnes, N., Lie, K. K., Magnus, P., Mjaaland, S., Reichborn-Kjennerud, T., Schjølberg, S., Øyen, A. S., Levin, B., Susser, E. S., Stoltenberg, C., & Lipkin, W. I. (2018). Prenatal fever and autism risk. Molecular psychiatry, 23(3), 759–766. https://doi.org/10.1038/mp.2017.119
Jiang, J., Jing, Y., Cost, G. J., Chiang, J. C., Kolpa, H. J., Cotton, A. M., Carone, D. M., Carone, B. R., Shivak, D. A., Guschin, D. Y., Pearl, J. R., Rebar, E. J., Byron, M., Gregory, P. D., Brown, C. J., Urnov, F. D., Hall, L. L., & Lawrence, J. B. (2013). Translating dosage compensation to trisomy 21. Nature, 500(7462), 296–300. https://doi.org/10.1038/nature12394
Kasparek, T., Theiner, P., & Filova, A. (2015). Neurobiology of ADHD From Childhood to Adulthood: Findings of Imaging Methods. Journal of attention disorders, 19(11), 931–943. https://doi.org/10.1177/1087054713505322
Katsnelson, A., Buzsáki, G., & Swann, J. W. (2014). Catastrophic childhood epilepsy: a recent convergence of basic and clinical neuroscience. Science translational medicine, 6(262), 262ps13.
Kozlowski, A. M., Matson, J. L., Horovitz, M., Worley, J. A., & Neal, D. (2011). Parents' first concerns of their child's development in toddlers with autism spectrum disorders. Developmental neurorehabilitation, 14(2), 72–78. https://doi.org/10.3109/17518423.2010.539193
Lainhart J. E. (2015). Brain imaging research in autism spectrum disorders: in search of neuropathology and health across the lifespan. Current opinion in psychiatry, 28(2), 76–82. https://doi.org/10.1097/YCO.0000000000000130
Lord, C., Risi, S., DiLavore, P. S., Shulman, C., Thurm, A., & Pickles, A. (2006). Autism from 2 to 9 years of age. Archives of general psychiatry, 63(6), 694–701. https://doi.org/10.1001/archpsyc.63.6.694
National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention. (2016). Autism Spectrum Disorder (ASD): Data & Statistics. Centers for Disease Control. https://www.cdc.gov/ncbddd/autism/data.html
Nei, M., Ngo, L., Sirven, J. I., & Sperling, M. R. (2014). Ketogenic diet in adolescents and adults with epilepsy. Seizure, 23(6), 439–442. https://doi.org/10.1016/j.seizure.2014.02.015
Norton, E. S., & Wolf, M. (2012). Rapid automatized naming (RAN) and reading fluency: implications for understanding and treatment of reading disabilities. Annual review of psychology, 63, 427–452. https://doi.org/10.1146/annurev-psych-120710-100431
Ozernov-Palchik, O., & Gaab, N. (2016). Tackling the 'dyslexia paradox': reading brain and behavior for early markers of developmental dyslexia. Wiley interdisciplinary reviews. Cognitive science, 7(2), 156–176. https://doi.org/10.1002/wcs.1383
Ozonoff, S., Young, G. S., Carter, A., Messinger, D., Yirmiya, N., Zwaigenbaum, L., Bryson, S., Carver, L. J., Constantino, J. N., Dobkins, K., Hutman, T., Iverson, J. M., Landa, R., Rogers, S. J., Sigman, M., & Stone, W. L. (2011). Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study. Pediatrics, 128(3), e488–e495. https://doi.org/10.1542/peds.2010-2825
Papavassiliou, P., Charalsawadi, C., Rafferty, K., & Jackson-Cook, C. (2015). Mosaicism for trisomy 21: a review. American journal of medical genetics. Part A, 167A(1), 26–39. https://doi.org/10.1002/ajmg.a.36861
Paulesu, E., Danelli, L., & Berlingeri, M. (2014). Reading the dyslexic brain: multiple dysfunctional routes revealed by a new meta-analysis of PET and fMRI activation studies. Frontiers in human neuroscience, 8, 830. https://doi.org/10.3389/fnhum.2014.00830
Presson, A. P., Partyka, G., Jensen, K. M., Devine, O. J., Rasmussen, S. A., McCabe, L. L., & McCabe, E. R. (2013). Current estimate of Down Syndrome population prevalence in the United States. The Journal of pediatrics, 163(4), 1163–1168. https://doi.org/10.1016/j.jpeds.2013.06.013
Schendel, D., & Bhasin, T. K. (2008). Birth weight and gestational age characteristics of children with autism, including a comparison with other developmental disabilities. Pediatrics, 121(6), 1155–1164. https://doi.org/10.1542/peds.2007-1049
Thapar, A., Cooper, M., Eyre, O., & Langley, K. (2013). What have we learnt about the causes of ADHD?. Journal of child psychology and psychiatry, and allied disciplines, 54(1), 3–16. https://doi.org/10.1111/j.1469-7610.2012.02611.x
Tolaymat, A., Nayak, A., Geyer, J. D., Geyer, S. K., & Carney, P. R. (2015). Diagnosis and management of childhood epilepsy. Current problems in pediatric and adolescent health care, 45(1), 3–17. https://doi.org/10.1016/j.cppeds.2014.12.002
Tomasi, D., & Volkow, N. D. (2014). Functional connectivity of substantia nigra and ventral tegmental area: maturation during adolescence and effects of ADHD. Cerebral cortex (New York, N.Y. : 1991), 24(4), 935–944. https://doi.org/10.1093/cercor/bhs382
Visser, S. N., Danielson, M. L., Bitsko, R. H., Holbrook, J. R., Kogan, M. D., Ghandour, R. M., Perou, R., & Blumberg, S. J. (2014). Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. Journal of the American Academy of Child and Adolescent Psychiatry, 53(1), 34–46.e2. https://doi.org/10.1016/j.jaac.2013.09.001
Willsey, A. J., & State, M. W. (2015). Autism spectrum disorders: from genes to neurobiology. Current opinion in neurobiology, 30, 92–99. https://doi.org/10.1016/j.conb.2014.10.015
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L., Fisher, E. M., & Strydom, A. (2015). A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nature reviews. Neuroscience, 16(9), 564–574. https://doi.org/10.1038/nrn3983
Witton, J., Padmashri, R., Zinyuk, L. E., Popov, V. I., Kraev, I., Line, S. J., Jensen, T. P., Tedoldi, A., Cummings, D. M., Tybulewicz, V. L. J., Fisher, E. M. C., Bannerman, D. M., Randall, A. D., Brown, J. T., Edwards, F. A., Rusakov, D. A., Stewart, M. G., & Jones, M. W. (2015). Hippocampal circuit dysfunction in the Tc1 mouse model of Down syndrome. Nature neuroscience, 18(9), 1291–1298. https://doi.org/10.1038/nn.4072
Young, L. J., & Barrett, C. E. (2015). Neuroscience. Can oxytocin treat autism? Science (New York, N.Y.), 347(6224), 825–826. https://doi.org/10.1126/science.aaa8120
Zuberi, S. M., & Symonds, J. D. (2015). Update on diagnosis and management of childhood epilepsies. Jornal de pediatria, 91(6 Suppl 1), S67–S77. https://doi.org/10.1016/j.jped.2015.07.003